Biyuantongqiao Granules Combined with Mometasone Furoate Nasal Spray for Allergic Rhinitis in Children

Abstract

The present study was conducted to observe the clinical efficacy of biyuantongqiao granules combined with mometasone furoate nasal spray in the treatment of allergic rhinitis in children. The patients in the control group were treated with mometasone furoate nasal spray (50 µg/press), and the patients in the observation group received biyuantongqiao granules (15 g × 10 bags) combined with mometasone furoate nasal spray, 15 mg/time. The total effective rate was significantly higher in the observation group (95.35%) than the control group (79.06%). The visual analogue scale scores in the two groups were decreased after treatment. The visual analogue scale scores in the observation group were significantly lower than those in the control group. The scores of nasal symptoms and signs and the serum levels of interleukin-4, vascular cell adhesion molecule-1, and immunoglobulin E in the two groups were decreased 4 weeks after treatment, while the serum levels of interleukin-12 and γ-interferon were increased. The differences in the observation group before and after treatment were greater than those in the control group. During treatment, there was no significant difference in the incidence of adverse reactions between the two groups. In conclusion, biyuantongqiao granules combined with mometasone furoate nasal spray can effectively improve the symptoms of allergic rhinitis patients, such as sneezing, nasal congestion, etc.